


BCR-ABL-IN-2

Cat. No.:	HY-18819
CAS No.:	897369-18-5
Molecular Formula:	C ₂₄ H ₂₅ Cl ₂ N ₅ O ₃
Molecular Weight:	502.39
Target:	Bcr-Abl
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC ₅₀ s of 57 nM, 773 nM for ABL1 ^{native} and ABL1 ^{T315I} , respectively.	
IC ₅₀ & Target	ABL1 ^{native} 57 nM (IC ₅₀)	ABL1 ^{T315I} 773 nM (IC ₅₀)
In Vitro	BCR-ABL-IN-2 (Compound 1) contains a urea moiety to allow a hydrogen bond with the conserved K271-E286 salt bridge of ABL1, a t-butyl moiety to bind into the hydrophobic spine at the third pocket position, and a 2,3-dichlorophenyl ring to stabilize the DFG-phenylalanine F382 in the Type II-out conformation. BCR-ABL-IN-2 exhibits an IC ₅₀ of 57 nM for ABL1 ^{native} and an IC ₅₀ of 773 nM for ABL1 ^{T315I} [1]. Despite ABL, BCR-ABL-IN-2 can also inhibit KDR, BRAF, p38 kinase with IC ₅₀ s of 1.8 μM, 0.23 μM, 6.3 nM, 43 nM, respectively[2].	

REFERENCES

[1]. Chan WW, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. *Cancer Cell*. 2011 Apr 12;19(4):556-68.

[2]. ARYL SULFONOHYDRAZIDES. US 2008/0113967 A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA